DC
PYXS icon

Decheng Capital’s Pyxis Oncology PYXS Stock Holding History

Decheng Capital’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$984K Hold
326,810
– – 0.13% 13
2026
Q1 		$477K Hold
326,810
– – 0.07% 14
2025
Q4 		$376K Hold
326,810
– – 0.05% 16
2025
Q3 		$726K Hold
326,810
– – 0.13% 20
2025
Q2 		$359K Hold
326,810
– – 0.09% 23
2025
Q1 		$320K Hold
326,810
– – 0.09% 24
2024
Q4 		$510K Hold
326,810
– – 0.11% 26
2024
Q3 		$1.2M Hold
326,810
– – 0.28% 22
2024
Q2 		$1.08M Hold
326,810
– – 0.33% 20
2024
Q1 		$1.39M Hold
326,810
– – 0.19% 19
2023
Q4 		$588K Buy
+326,810
New +$560K 0.16% 23

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Decheng Capital's PYXS Position: Q2 2026 in Review

Decheng Capital held its Pyxis Oncology (PYXS) position steady in Q2 2026 at 326,810 shares worth $984K. The position accounts for 0.13% of the portfolio, ranked #13.

Decheng Capital first reported a position in PYXS in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.39M in Q1 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Decheng Capital held 326,810 shares of Pyxis Oncology worth $984K as of Q2 2026.
  • Decheng Capital left its Pyxis Oncology share count unchanged in Q2 2026.
  • Pyxis Oncology made up 0.13% of Decheng Capital's portfolio in Q2 2026, its #13 holding.
  • Decheng Capital first reported a position in Pyxis Oncology in Q4 2023 and has held it in 11 quarters since.
  • Decheng Capital's Pyxis Oncology position peaked at $1.39M in Q1 2024.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Decheng Capital's 13F filing for Q2 2026, filed 14 Aug 2026.